ReliaWireMoesin Regulates Cancer Immunity, May Be Immunotherapy TargetReliaWireThe protein is a potential therapeutic target for cancer immunotherapy, Medical University of South Carolina (MUSC) investigators report. Their findings show that TGF-beta a… Continue reading
Immunotherapy Success in Gynecologic Cancers Will Require a Refined ApproachTargeted OncologyThough immunotherapy with PD-1/PD-L1 inhibitors has been slower to develop in gynecologic cancers than in several other solid tumors, researchers are eyeing ne… Continue reading
Forbes |
CRISPR Could Change The World, But Right Now $90 Million Is Enough
Forbes There’s nothing like a business development deal to give a sense of scale to a mountain of scientific hype. That’s what happened this morning, when Allergan, the eye-drug and Botox maker, signed a deal with Editas Medicine, which owns licenses to the … Allergan, Editas partner on CRISPR tech in eye diseasesFierceBiotech Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseasesEndpoints News Editas and Allergan Partner on Multiple CRISPR Eye Disease ProgramsGenetic Engineering & Biotechnology News BioPharma Dive –StreetInsider.com –Xconomy all 28 news articles » |
Forbes |
CRISPR Could Change The World, But Right Now $90 Million Is Enough
Forbes There’s nothing like a business development deal to give a sense of scale to a mountain of scientific hype. That’s what happened this morning, when Allergan, the eye-drug and Botox maker, signed a deal with Editas Medicine, which owns licenses to the … Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseasesEndpoints News Allergan, Editas partner on CRISPR tech in eye diseasesFierceBiotech Allergan makes a deal with Editas to License CRISPR Programs for Eye DiseaseLabiotech.eu (blog) Fortune –MedCity News –GenomeWeb all 86 news articles » |
|
Allergan taps CRISPR biotech Editas in eye care deal
BioPharma Dive Intellia Therapeutics and CRISPR Therapeutics have both inked agreements delivering $75 million in upfront money, and Bayer has committed $300 million in funding for a joint venture with CRISPR Therapeutics. Other deals, including Editas’ prior deal … |
MedCity News |
Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal
GenomeWeb Under the terms of the deal, Allergan subsidiary Allergan Pharmaceuticals International Limited will have exclusive options to license up to five of Editas’ ocular drug candidates including LCA10, its preclinical treatment for Leber congenital … Allergan makes a deal with Editas to License CRISPR Programs for Eye DiseaseLabiotech.eu (blog) Allergan and Editas announce $90M CRISPR dealMedCity News |